Zacks Investment Research cut shares of Atyr Pharma Inc. (NASDAQ:LIFE) from a buy rating to a hold rating in a research note issued to investors on Wednesday.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
A number of other brokerages have also recently commented on LIFE. JPMorgan Chase & Co. decreased their price target on Atyr Pharma from $15.00 to $10.00 and set an overweight rating on the stock in a research note on Thursday, August 11th. Citigroup Inc. boosted their target price on Atyr Pharma from $3.00 to $4.00 and gave the company a neutral rating in a research note on Tuesday, August 16th. Finally, BMO Capital Markets set a $8.00 target price on Atyr Pharma and gave the company a hold rating in a research note on Thursday, October 6th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Atyr Pharma has an average rating of Hold and an average target price of $6.50.
Shares of Atyr Pharma (NASDAQ:LIFE) opened at 2.86 on Wednesday. The stock has a 50 day moving average of $3.11 and a 200-day moving average of $3.24. The company’s market cap is $67.83 million. Atyr Pharma has a 12 month low of $2.48 and a 12 month high of $13.26.
Atyr Pharma (NASDAQ:LIFE) last released its earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.06. Equities analysts forecast that Atyr Pharma will post ($2.56) earnings per share for the current year.
Large investors have recently modified their holdings of the company. A.R.T. Advisors LLC boosted its stake in shares of Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock valued at $108,000 after buying an additional 18,410 shares during the last quarter. State Street Corp boosted its stake in shares of Atyr Pharma by 51.8% in the first quarter. State Street Corp now owns 68,285 shares of the company’s stock valued at $270,000 after buying an additional 23,290 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Atyr Pharma during the second quarter valued at $101,000. Bridgeway Capital Management Inc. purchased a new stake in shares of Atyr Pharma during the second quarter valued at $133,000. Finally, Jackson Park Capital LLC purchased a new stake in shares of Atyr Pharma during the second quarter valued at $183,000. 44.75% of the stock is currently owned by institutional investors.
Atyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.